MedPath

Aliskiren

Generic Name
Aliskiren
Brand Names
Rasilez, Tekturna, Tekturna Hct
Drug Type
Small Molecule
Chemical Formula
C30H53N3O6
CAS Number
173334-57-1
Unique Ingredient Identifier
502FWN4Q32
Background

Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.

Indication

Aliskiren is used for the treatment of hypertension in children above 6 years and adults. This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.

Associated Conditions
Hypertension
Clinical Trials
Related News

Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan

Phase 4
Withdrawn
Conditions
Hypertension
Diabetes Mellitus
Interventions
First Posted Date
2011-08-04
Last Posted Date
2012-03-06
Lead Sponsor
Hospital Universitario Pedro Ernesto
Registration Number
NCT01409408
Locations
🇧🇷

Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil

Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients

Phase 4
Conditions
Hypertension
Dialysis
Interventions
First Posted Date
2011-07-14
Last Posted Date
2012-07-10
Lead Sponsor
University of Campania "Luigi Vanvitelli"
Target Recruit Count
350
Registration Number
NCT01394770
Locations
🇮🇹

Second Univesity of Naples, Naples, Italy

Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects

Phase 4
Terminated
Conditions
Diabetes
Pre-hypertension
Hypertension
Interventions
Drug: Placebo/sugar pill
First Posted Date
2011-05-06
Last Posted Date
2017-05-11
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
21
Registration Number
NCT01349114
Locations
🇺🇸

UAB, Birmingham, Alabama, United States

Aliskiren on Retinal Vasculature Treatment Study

Phase 3
Completed
Conditions
Arterial Hypertension
Interventions
Drug: Placebo
First Posted Date
2011-03-18
Last Posted Date
2018-01-12
Lead Sponsor
University of Erlangen-Nürnberg Medical School
Target Recruit Count
56
Registration Number
NCT01318395
Locations
🇩🇪

Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Nürnberg, Germany

The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients

Phase 4
Conditions
Peritoneal Membrane Failure
Interventions
Drug: placebo
First Posted Date
2011-03-01
Last Posted Date
2011-03-10
Lead Sponsor
Chulalongkorn University
Target Recruit Count
100
Registration Number
NCT01305850
Locations
🇹🇭

Chulalongkorn University, Bangkok, Thailand

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

First Posted Date
2011-02-24
Last Posted Date
2013-01-30
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
8
Registration Number
NCT01302899
Locations
🇳🇱

Novartis Investigative Site, Leeuwarden, Netherlands

Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure

Not Applicable
Conditions
Heart Failure
Interventions
First Posted Date
2011-02-17
Last Posted Date
2011-02-17
Lead Sponsor
Taipei Veterans General Hospital, Taiwan
Target Recruit Count
120
Registration Number
NCT01298258
Locations
🇨🇳

Taipei Veterans General Hospital, Taipei, Taiwan

Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients

Phase 4
Completed
Conditions
Hypertension
Chronic Kidney Disease
Interventions
First Posted Date
2011-01-26
Last Posted Date
2012-10-22
Lead Sponsor
Jichi Medical University
Target Recruit Count
23
Registration Number
NCT01284114
Locations
🇯🇵

Kurosu Hospital, Sakura, Tochigi, Japan

🇯🇵

Niimi city Yukawa National health insurance clinic, Niimi, Okayama, Japan

🇯🇵

Konan Hospital, Oyama, Tochigi, Japan

and more 1 locations

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

First Posted Date
2010-12-14
Last Posted Date
2014-04-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
2336
Registration Number
NCT01259297
Locations
🇸🇪

Novartis Investigative Site, Stockholm, Sweden

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

Not Applicable
Terminated
Conditions
Insulin Sensitivity
Aortic Compliance
Diastolic Function
Interventions
First Posted Date
2010-12-02
Last Posted Date
2018-02-13
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
24
Registration Number
NCT01252238
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy